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Background: Premorbid metabolic syndrome (pre-MetS) is a cluster of cardiometabolic risk factors characterised
by central obesity, elevated fasting glucose, atherogenic dyslipidaemia and hypertension without established
cardiovascular disease or diabetes. Community pharmacies are in an excellent position to develop screening
programmes because of their direct contact with the population.
The main aim of the study was to determine the prevalence of pre-MetS in people who visited community pharmacies
for measurement of any of its five risk factors to detect the presence of other risk factors. The secondary aims were to
study the presence of other cardiovascular risk factors and determine patients’ cardiovascular risk.
Methods: Cross-sectional, descriptive, multicentre study. Patients meeting selection criteria aged between 18 and 65
years who visited participating community pharmacies to check any of five pre-MetS diagnostic factors were included.
The study involved 23 community pharmacies in Catalonia (Spain). Detection criteria for pre-MetS were based on the
WHO proposal following IDF and AHA/NHBI consensus. Cardiovascular risk (CVR) was calculated by Regicor and Score
methods. Other variables studied were smoking habit, physical activity, body mass index (BMI), and pharmacological
treatment of dyslipidemia and hypertension. The data were collected and analysed with the SPSS programme.
Comparisons of variables were carried out using the Student’s T-test, Chi-Squared test or ANOVA test. Level of
significance was 5% (0.05).
Results: The overall prevalence of pre-MetS was 21.9% [95% CI 18.7-25.2]. It was more prevalent in men, 25.5%
[95% CI 22.1-28.9], than in women, 18.6% [95% CI 15.5-21.7], and distribution increased with age. The most common
risk factors were high blood pressure and abdominal obesity. About 70% of people with pre-MetS were sedentary and
over 85% had a BMI ≥25 Kg/m2. Some 22.4% had two metabolic criteria and 27.2% of patients with pre-MetS had no
previous diagnosis.
Conclusions: The prevalence of pre-MetS in our study (21.9%) was similar to that found in other studies carried out
in Primary Care in Spain. The results of this study confirm emergent cardiometabolic risk factors such as hypertension,
obesity and physical inactivity.
Our study highlights the strategic role of the community pharmacy in the detection of pre-MetS in the apparently
healthy population.
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The great increase in the incidence of cardiovascular
disease (CVD) and type 2 diabetes mellitus (T2DM)
among patients throughout the developed and developing
world means that physicians and other care providers
have to be aware of the risk factors for these conditions.
They should be able to identify patients at risk to initi-
ate treatment to prevent these diseases [1]. Identifying
individuals at risk of chronic diseases is the first step
towards preventive measures [2].
Metabolic syndrome (MetS) is a cluster of cardiovascular
risk factors. Although there are various definitions of meta-
bolic syndrome, the syndrome’s common pathophysiology
is insulin resistance and a prominent clinical feature of
this syndrome is abdominal or central obesity [3]. The
term “cardiometabolic risk” is now starting to gain greater
acceptance as it includes the entire cluster of classic
cardiovascular risk factors and other emerging factors
such as those related to abdominal obesity and insulin
resistence [4]. It is known that patients who develop
CVD or T2DM have common histories of disorders of
metabolic origin [1]. The criteria for identifying MetS
includes five variables, namely, abdominal obesity, raised
triglycerides, low high-density lipoproteins (HDL-chol-
esterol), elevated blood pressure and impaired fasting
glucose state [5]. The lack of consensus on diagnostic
criteria does not allow comparison of distinct MetS
prevalence data. However, irrespective of the criteria
used, the reality is that MetS is indeed highly prevalent,
especially in developed countries [5,6]. Initial studies in
the U.S recognise MetS as a principal health problem
in developed countries with considerable social and
economic consequences [6].
Some years ago, International Diabetes Federation (IDF)
and American Heart Association/National Heart, Lung
and Blood Institute (AHA/NHLBI) representatives at-
tempted to resolve the remaining differences between
definitions of metabolic syndrome [4]. They agreed that
abdominal obesity should not be a prerequisite for diag-
nosis but that it is 1 of 5 criteria, and that the presence
of any 3 of 5 risk factors constitutes a diagnosis of
metabolic syndrome.
Concerning the metabolic syndrome concept, in 2010
the World Health Organization (WHO) proposed that
MetS should be considered a premorbid condition [7].
Therefore, screenings for pre-MetS should exclude indi-
viduals with established diabetes or known cardiovascular
disease [7]. Exclusion of these patients is the main differ-
ence between the metabolic syndrome and premorbid
metabolic syndrome concepts.
Nowadays, pre-MetS has been receiving attention not
only in hospital-based medicine but also in primary care
(PC) and the community pharmacy. Since epidemio-
logical studies [2,6,8,9] suggest that >25% of the generalpopulation will gradually develop insulin resistance, it
would appear that this pathology will increasingly be
diagnosed and treated within the ambit of PC. More-
over, screening will be included in the list of priorities
of various public health-care authorities [6].
Community pharmacies are in an excellent position to
develop screening programmes to identify individuals
at risk of developing CVD or T2DM because of their
contact with citizens whether they are ill or not [10].
The quality of care offered by the pharmacist, who can
also provide health interventions to individuals [10], allows
the extension of individual clinical interventions to a larger
percentage of the population that does not visit the doctor
or seek primary or hospital care.
The main aim of the study was to determine the preva-
lence of pre-MetS in people who visited community phar-
macies for measurement of any of its five risk factors to
detect the presence of other risk factors. The secondary
aims were to study the presence of other cardiovascular
risk factors and determine patients’ cardiovascular risk.
Methods
Design
Cross-sectional, descriptive, multicentre study to deter-
mine the prevalence of premorbid metabolic syndrome
in patients who visit community pharmacies.
Study population
Individuals aged between 18 and 65 years who visited
the participating community pharmacies to check any
of the five pre-MetS diagnostic factors during the
11-month study period (Nov’, 2009-Oct’, 2010) were
recruited sequentially. Those patients who spontaneously
visited the community pharmacy to measure any of the
five risk factors were invited to participate in the study.
The sample consisted of 650 patients meeting the follow-
ing inclusion criteria: not having diabetes, not having
suffered any previous cardiovascular episode, not being
pregnant, not presenting cognitive impairment that inter-
feres with understanding of the study, and agreeing to
participate in it (Figure 1). Written informed consent
was obtained for all participants (no children were studied).
The Germans Trias i Pujol Hospital Ethics Committee
revised and approved the study (EO-12-038). This sample
size allows us to estimate the prevalence of pre-MetS
with a precision level of ±3% and an α risk of 0.05 for
an estimated theoretical pre-MetS prevalence of 20%.
Setting
The study involved 23 volunteer community pharmacies
situated to the northeast (Barcelona Nord and Maresme)
and the southwest (Costa Ponent) of Barcelona City,
Catalonia (Spain), from a total of 553 community pharma-
cies who provide pharmaceutical services to approximately
Figure 1 General study schema. Cross-sectional, descriptive,
multicentre study to determine the prevalence of premorbid metabolic
syndrome in patients who visit community pharmacies.
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ditation to supervise senior pharmacy students from
the University of Barcelona. The pharmacists and the
senior students received 4-hour training session prior
to the study.
Variables studied
All data were collected by pharmacists using a data
collection sheet. Age, gender, smoking habit, physical
activity and pharmacological treatment of pre-MetS
diagnostic factors were self-reported and noted during
a clinical interview with the patients studied at the
pharmacies. Physical activity was evaluated according
the Baleares Primary Care Guide [11]. According to
this guide, the patient was not considered sedentary if
he or she engaged in physical exercise for 30 minutes
or more, four or five times per week. Physical exercise
was defined as any activity which caused sweating
[11]. Smoking habit was considered absent when the
participant had not smoked during the previous year.
Anthropometrics were obtained with the participant
wearing light clothing and barefoot. Body mass index
(BMI) (Kg/m2) was calculated through weight (Kg)
and height (m) measured by calibrated digital scales
and stadiometers [12]. Fasting glucose (FG) (mg/dl),
total cholesterol (mg/dl) and triglycerides (mg/dl) were
measured with Reflotron® (Roche Diagnostics) after
an overnight fast (lasting at least 8 hours) and HDL-
cholesterol (mg/dl) was obtained from a Blood TestReport taken within the previous 3 months. Abdominal
obesity (AO) was determined by the measurement of
waist circumference (WC) midway between the infer-
ior margin of the ribs and the superior border of the
iliac crest. Systolic and diastolic blood pressure (SBP
and DBP) were measured twice with validated and cali-
brated electronic sphygmomanometers after 5 minutes
rest. Cardiovascular risk was calculated according to
Framingham-Regicor [13,14] predictive equations cali-
brated for Girona (Spain) and according to the Score
[13] project for European population at low risk.
Framingham-Regicor risk tables have been adapted
and validated with data from the population of Girona
(Spain) in the VERIFICA study [14,15].
To determine the prevalence of pre-MetS in our study,
we used the MetS defining criteria according to the
most recent IDF and AHA/NHLBI consensus [4] and
the WHO [7] premorbid condition, i.e., individuals not
diagnosed with cardiovascular disease or diabetes and
having at least three of the five risk factors: Waist
circumference (WC): ♂ ≥ 102 cm or ♀ ≥ 88 cm (for
Europeans); triglycerides (TG): ≥150 mg/dl (1.7 mmol/L)
or taking lipid-regulating medication; high density lipo-
proteins (HDL-cholesterol): ♂ <40 mg/dL (1.0 mmol/L),
♀ <50 mg/dL (1.3 mmol/L) or drug treatment for reduced
HDL-cholesterol; blood pressure (BP): ≥130/85 mm Hg or
taking antihypertensive medication, and fasting glucose
(FG): ≥100 mg/dL (5.6 mmol/L).Statistical analysis
Statistical analysis was conducted with the SPSS prog-
ramme (version 15.0). The variables measured on a quanti-
tative scale are expressed as meanss (±Standard Deviation)
and those variables measured on a qualitative scale are
expressed as percentages (95% Confidence Interval). Com-
parison between quantitative variables was carried out
using the Student’s T-Test when they were dichotomous,
and with the ANOVA test where there were more than
two categories. Comparison between qualitative variables
was performed with the Chi-Squared test. The significance
level was set at 5%.Results
Description of study population
Figure 1 shows the general outline of the study, the
number of patients who were excluded and the distinct
reasons for exclusion.
Table 1 (n = 650) summarises the baseline characteristics
of the included patients segregated by gender. A total of
51.8% (337) of the participants were female and the overall
mean age of included patients was 48.4 ± 12.5 years. There
were no statistically significant differences between the
men’s and women’s mean ages.
Table 1 Baseline characteristics of studied population according to gender
Total n = 650 Men n = 313 Women n = 337 p
Age1 (years) 48.4 (SD = 12.5) 48.9 (SD = 12.5) 48.0 (SD = 12.5) 0.341
Waist C1 (cm) 92.3 (SD = 13.6) 97.7 (SD = 11.6) 87.1 (SD = 13.3) <0.001
BMI1 (kg/m2) 26.4(SD = 4.5) 27.1 (SD = 4.1) 25.7 (SD = 4.7) <0.001
Fasting glucose1 (mg/dl) 93.6 (SD = 14.6) 95.5 (SD = 14.6) 91.9 (SD = 14.3) 0.002
Total cholesterol1 (mg/dl) 204.9 (SD = 39.6) 201.8 (SD = 41.2) 207.8 (SD = 37.8) 0.051
HDL-cholesterol1 (mg/dl) 58.7 (SD = 14.7) 55.4 (SD = 13.4) 61.8 (SD = 15.3) <0.001
Triglyceride1 (mg/dl) 123.0 (SD = 83.4) 138.7 (SD = 102.6) 108.3 (SD = 56.5) <0.001
SBP1 (mm Hg) 127.2 (SD = 16.2) 130.5 (SD = 16.1) 124.2 (SD = 15.7) <0.001
DBP1 (mm Hg) 77.3 (SD = 10.5) 79.5 (SD = 10.2) 75.2 (SD = 10.3) <0.001
CVR1 (Score) 1.5 (SD = 1.9) 2.4 (SD = 2.1) 0.8 (SD = 1.1) <0.001
CVR1 (Regicor) 3.4 (SD = 2.3) 3.9 (SD = 2.6) 2.9 (SD = 1.9) <0.001
AC drugs2 30.0 (26.5-33.5) 33.5 (28.3-38.7) 26.7 (22.0-31.4) 0.060
AH drugs2 32.3 (28.7-35.9) 40.3 (34.9-45.7) 24.9 (20.3-29.5) <0.001
Smoking habit2 30.0 (26.5-33.5) 34.8 (29.5-40.1) 25.5 (20.8-30.2) 0.010
Physical inactivity2 58.5 (54.7-62.3) 52.7 (47.2-58.2) 63.8 (58.7-68.9) 0.005
p ≤ 0.05 is considered to be statistically significant.
1Data are expressed as means (Standard Deviation).
2Data are expressed as percentages (95% confidence interval).
Waist C waist circumference; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; CVR cardiovascular risk; AC Drugs pharmacological
treatment of hypercholesterolemia or hypertriglyceridemia; AH Drugs pharmacological treatment of hypertension.
Figure 2 Prevalence of premorbid metabolic syndrome based
on the WHO proposal and their five diagnostic factors by
gender. Data are expressed as percentages. Pre-MetS: premorbid
metabolic syndrome; TG: Triglycerides; GLU: fasting glucose; HDLc:
HDL-cholesterol; BP: blood pressure; AO: abdominal obesity.
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[95% CI 26.0-26.7] and there were statistically significant
differences by gender (27.1 Kg/m2 [95% CI 26.7-27.6]
in men and 25.7 Kg/m2 [95% CI 25.2-26.2] in women).
Some 42.3% of the study population had normal weight
(BMI < 25), 39.5% were overweight (25 ≤ BMI < 30) and
18.2% were obese (BMI ≥ 30). 58.5% of the participants
were considered physically inactive and this was statis-
tically more prevalent in women than in men.
Some 49.8% (323) were receiving pharmacological
treatment for at least one of the five pre-MetS diagnostic
factors. About 30% of participants received pharmaco-
logical treatment for hypertension or dyslipidaemia and
13.4% (87) for both.
Of these 650 patients, 29 (4.5%) were excluded from
the sample due to a lack of more than two diagnostic
risk-factor values making it difficult to estimate a diagno-
sis for pre-MetS in these individuals. Triglycerides and
HDL-cholesterol were the most difficult values to collate.
The pre-MetS risk-factor prevalences were: elevated
blood pressure in 49.1% (305), abdominal obesity in 40.3%
(250), elevated fasting glucose in 27.5% (170), elevated
triglycerides in 20.1% (122) and low HDL-cholesterol
in 16.8% (99). All risk factors were more prevalent in
men than women except abdominal obesity and HDL-
cholesterol while the differing percentages between
the genders were statistically significant (Figure 2).
Only 20.5% (127) of study population did not present
any of the five pre-MetS diagnostic criteria risk factors,
31.7% (197) presented one of these metabolic criteriaand 22.4% (139) had two. Regarding the 139 participants
with two risk factors, 66.2% (92) had altered blood pressure
and 59.0% (82) abdominal obesity.
Among the study participants, we found a high correl-
ation between abdominal obesity and BMI.
The prevalence of premorbid metabolic syndrome in the
study population
The prevalence of pre-MetS was 21.9% [95% CI 18.7-25.2]
and was more prevalent in the men 25.5% [95% CI
22.1-28.9] than in the women 18.6% [95% CI 15.5-21.7%]
studied (Figure 2). Some 59.6% of patients with pre-MetS
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and only 5.1% had all five risk factors.
Of the 136 patients who had pre-MetS, 37 (27.2%)
had not been previously diagnosed with dyslipidaemia
or hypertension.
Table 2 (n = 621) shows information on the quantitative
variables studied in two groups: those with and without
pre-MetS. We should point out that all of these variables
were statistically different in the two groups. Participants
with pre-MetS were older than patients without it. Fur-
thermore, people with this syndrome also presented
higher values in other risk factors not included in the
diagnostic criteria (BMI, total cholesterol, CVR Score
and CVR Regicor) than participants without pre-MetS.
Table 3 (n = 621) shows the percentages of the qualita-
tive variables studied divided into groups corresponding
to those with and without pre-MetS. All variables showed
statistically significant differences between groups except
the number of smokers.
Table 4 (n = 621) shows that the prevalence of pre-
MetS increased with age. This prevalence was about four
times higher in older people than in younger patients.
Over two-thirds of participants with pre-MetS were
more than 53 years old. In addition, it was observed that
the prevalence by the different age groups classified by
gender showed no statistically significant differences.
As mentioned above, Body Mass Index (BMI) is a car-
diometabolic risk factor not included in the pre-MetS
diagnostic criteria. In Table 3, it can be seen that 87.5%
of participants with pre-MetS were overweight or obese,
that is to say, they had a BMI ≥ 25. Table 5 shows the
statistically significant differences observed in all quanti-
tative variables between subjects with BMI < 25 and
those with BMI ≥ 25. When comparing individuals with
a BMI between BMI ≥ 25 and BMI ≥ 30, almost none ofTable 2 Quantitative variables of the subjects as a function o
on the WHO proposal
Total n = 621 Pre-M
Age (years) 48.5 (SD = 12.4) 54.
Waist C (cm) 92.0 (SD = 13.6) 103.
BMI (kg/m2) 26.3 (SD = 4.5) 29.
Fasting glucose(mg/dl) 93.7 (SD = 14.3) 105.
Total cholesterol (mg/dl) 205.3 (SD = 39.9) 219.
HDL-cholesterol (mg/dl) 58.8 (SD = 14.7) 49.2
Triglyceride (mg/dl) 122.7 (SD = 83.4) 189.3
SBP (mm Hg) 126.8 (SD = 16.2) 138.
DBP (mm Hg) 77.0 (SD = 10.4) 82.7
CVR (Score) 1.5 (SD = 1.9) 2.5
CVR (Regicor) 3.3 (SD = 2.3) 4.8
p ≤ 0.05 is considered to be statistically significant.
Data are expressed as means (Standard Deviation).
Pre-MetS premorbid metabolic syndrome; BMI body mass index; SBP systolic bloodthe parameters studied showed statistically significant
differences. However, statistically significant differences
were observed in some MetS diagnostic criteria risk
factors (triglycerides, waist circumference and systolic
blood pressure).
Figure 3 shows the BMI error bars by gender according
to the presence or absence of pre-MetS. It was determined
that men and women who presented pre-MetS had similar
BMI. However, men without pre-MetS had a significantly
higher BMI than women without pre-MetS.
Figures 4 and 5 show the cardiovascular risk error bars
(Regicor and Score, respectively) according to the pres-
ence or absence of pre-MetS and physical inactivity. In
both figures, we can see that sedentary patients with
pre-MetS had a higher cardiovascular risk than physic-
ally active patients. This difference was less significant in
patients without pre-MetS.
Discussion
The main advantages of these screenings for primary
prevention carried out in community pharmacies are the
proximity to the patients, the availability of quick, easy-
to-apply screening tests and, where necessary, the option
of carrying out a pharmaceutical intervention on the
spot. A further positive aspect is that it is not only ill
patients who visit the community pharmacy to pick up
medication but also apparently healthy individuals who
have other reasons to attend such as weight or arterial
pressure control.
In our study, slightly more than half (50.2%) of study
participants had not received any pharmacological treat-
ment for any of the five pre-MetS diagnostic factors, that
is, they were apparently healthy participants. Among these
patients who were not taking any medication for any of
the factors, 12.1% had pre-MetS. Moreover, a little moref the diagnosis of premorbid metabolic syndrome based
etS n = 136 Non Pre-MetS n = 485 p
5 (SD = 9.2) 46.8 (SD = 12.7) <0.001
3 (SD = 11.8) 88.8 (SD = 12.3) <0.001
8 (SD = 4.6) 25.3 (SD = 3.9) <0.001
5 (SD = 17.9) 90.3 (SD = 10.9) <0.001
5 (SD = 41.1) 201.4 (SD = 38.7) <0.001
(SD = 13.4) 61.5 (SD = 14.0) <0.001
(SD = 132.7) 103.8 (SD = 48.8) <0.001
3 (SD = 15.5) 123.6 (SD = 14.9) <0.001
(SD = 10.7) 75.4 (SD = 9.6) <0.001
(SD = 2.3) 1.2 (SD = 1.5) <0.001
(SD = 2.6) 2.8 (SD = 1.9) <0.001
pressure; DBP diastolic blood pressure; CVR cardiovascular risk.
Table 3 Qualitative variables of the subjects as a function of the diagnosis of premorbid metabolic syndrome based on
the WHO proposal
Total n = 621 Pre-MetS n = 136 Non Pre-MetS n = 485 p
Sex ♂ 48.0 (44.1-51.9) 55.9 (47.6-64.2) 45.8 (41.4-50.2)
♀ 52.0 (48.1-55.9) 44.1 (35.8-52.4) 54.2 (49.8-58.6) <0.001
AC drugs 30.0 (26.4-33.6) 49.3 (40.9-57.7) 24.5 (20.7-28.3) <0.001
AH drugs 32.7 (29.0-36.4) 49.3 (40.9-57.7) 28.0 (24.0-32.0) <0.001
Smoking habit 30.1 (26.5-33.7) 27.9 (20.4-35.4) 30.7 (26.6-34.8) 0.597
Physical inactivity 58.9 (55.0-62.8) 69.9 (62.2-77.6) 55.9 (51.5-60.3) 0.004
BMI <25 42.4 (38.5-46.3) 12.5 (7.0-18.1) 50.7 (46.6-55.2)
≥25 57.6 (53.7-61.5) 87.5 (81.9-93.1) 49.3 (44.9-53.7) <0.001
p ≤ 0.05 is considered to be statistically significant.
Data are expressed as percentages (95% Confidence Interval).
Pre-MetS premorbid metabolic syndrome; AC drugs: pharmacological treatment of hypercholesterolemia or hypertriglyceridemia; AH Drugs: pharmacological
treatment of hypertension.
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previously diagnosed with dyslipidemia or hypertension.
These two findings highlight the value of the screening
service provided by community pharmacies.
To date, the recent concept of metabolic syndrome as a
premorbid condition [7] has rarely been used in prevalence
studies [2,5,6,8,9]. According to the literature worldwide,
there are few published studies using this new concept
[16,17]. One of them is the DARIOS [16] study which
included approximately 24,000 Spanish patients in primary
care and found a higher prevalence of pre-MetS (24%)
than in our study (21.9% [95% CI 18.7-25.2]). A possible
explanation for this could be the older age range (35–74
years). As in our study, pre-MetS was more prevalent in
men (26% [95% CI 23–28]) than in women (24% [95% CI
21–27]). The distribution of pre-MetS by gender and age
was similar in both studies. In our study, the prevalence of
pre-MetS was higher in men up to 60 years old and above
61 years it was higher in women. In the DARIOS [16]
study, prevalence was higher in men up to 54 years of
age, similar in men and in women between 55 and
64 years, and above 65 years it was higher in women.
As the DARIOS [16] study also mentioned, an important
factor that could explain the higher prevalence in olderTable 4 Sex and age-specific prevalence of premorbid
Metabolic Syndrome based on WHO proposal
Prevalences of Pre-MetS
Total (%) Men (%) Women (%) p
Age ranges:
18-39 years 8.7 (14/161) 10.7 (8/75) 7.0 (6/86) 0.419
40-52 years 17.9 (30/168) 25.0 (21/84) 10.7 (9/84) 0.026
53-60 years 28.1 (43/153) 34.9 (22/63) 23.3 (21/90) 0.144
61-65 years 35.3 (49/139) 32.9 (25/76) 38.1 (24/63) 0.594
Total 21.9 (136/621) 25.5 (76/298) 18.6 (60/323) 0.041women is the menopause. The reduction in female hor-
monal production involves alterations in the lipid profile
and increases abdominal obesity. These cardiometabolic
risk factors may all be accompanied by an increase in
insulin resistance [18,19].
Another study which considered the premorbid condi-
tion is the HERMEX [19] study. It included about 2,800
Spanish patients in primary care in Badajoz (Spain).
The participants in this study were randomly recruited
in accordance with the population census and were
between 25 and 79 years old. The estimated prevalence
of pre-MetS in the HERMEX study was 20.8% (95% CI:
19.3-22.3%). In common with our findings, it was more
prevalent in men (23.5% [95% CI 21.2-25.8]) than in
women (18.5% [95% CI 16.5-20.4]) and distribution by
gender and age was very similar to that found in the
DARIOS [16] study.
In contrast, there are many studies of MetS prevalence
(with diabetic patients and previous CVD included) which
obtained distinct prevalence values depending on diagnos-
tic criteria (IDF, NCEP-ATPIII, etc.) and almost all were
higher than in our study [6,8,9,20,21]. The exclusion
of patients with T2DM or previous CVD significantly
decreases the prevalence of MetS and, at the same time,
allows enhancement of primary prevention of cardiometa-
bolic diseases [7,22,23].
We were able to determine the most common pre-MetS
risk factors in people who visit community pharmacies.
As in the DARIOS [16] and HERMEX [17] studies, the
most prevalent risk factors were hypertension and abdom-
inal obesity, followed by raised fasting glucose, increased
triglycerides and, finally, low HDL-cholesterol. As in
these two studies, elevated fasting glucose and raised
triglycerides were more common in men and low HDL-
cholesterol and abdominal obesity were more common
in women. In contrast to the DARIOS [16] and HERMEX
[19] studies, we observed statistically significant differences
Table 5 Studied variables of the subjects according to BMI categories
Body mass index (Kg/m2)
BMI < 25 n = 263 25 ≤ BMI < 30 n = 245 BMI ≥ 30 n = 113
Age (Years) 44.0 (SD = 13.6) 51.4 (SD = 10.4) 52.4 (SD = 10.2)
p <0.001 0.765
Fasting glucose (mg/dl) 89.2 (SD = 10.9) 96.0 (SD = 15.8) 99.0 (SD = 14.8)
p <0.001 0.132
Total cholesterol (mg/dl) 198.2 (SD = 40.5) 210.4 (SD = 39.5) 211.1 (SD = 37.1)
p 0.001 0.986
Triglycerides (mg/dl) 99.5 (SD = 55.1) 131.9 (SD = 81.0) 155.0 (SD = 120.8)
p <0.001 0.032
HDL-cholesterol (mg/dl) 62.7 (SD = 15.3) 56.1 (SD = 13.8) 55.4 (SD = 13.3)
p <0.001 0.913
Waist circumference (cm) 82.1 (SD = 9.7) 95.3 (SD = 8.9) 107.3 (SD = 11.0)
p <0.001 <0.001
SBP (mm Hg) 121.9 (SD = 15.3) 128.6 (SD = 15.7) 134.4 (SD = 15.8)
p <0.001 0.003
DBP (mm Hg) 74.3 (SD = 10.2) 78.6 (SD = 9.5) 80.1 (SD = 10.7)
p <0.001 0.396
CVRSCORE (%) 1.0 (SD = 1.3) 1.8 (SD = 2.1) 1.8 (SD = 2.0)
p <0.001 0.991
CVR REGICOR (%) 2.6 (SD = 1.7) 3.7 (SD = 2.5) 3.8 (SD = 2.4)
p <0.001 0.964
p ≤ 0.05 is considered to be statistically significant.
Data are expressed as means (Standard Deviation).
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; CVR cardiovascular.
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more prevalent in men than in women.
Unfortunately, in comparative studies [16,17], other risk
factors such as physical inactivity or BMI with premorbid
condition were not studied, that is, patients with T2DM
or previous CVD were not excluded to determine the
prevalences of these other risk factors.
There are many risk factors highly associated with poor
nutrition and sedentary lifestyle [24,25]. In community
pharmacies, the pharmacist may suggest several non-
pharmacological interventions such as nutritional and
lifestyle modifications [26,27]. The most suitable subjects
for these interventions are those who have pre-MetS
(21.9%) and patients with two of the five diagnostic
criteria (22.4%).
On the one hand, the pharmacist can promote primary
prevention of CVD and T2DM through encouraging a
healthy lifestyle. The pharmacist can provide programmes
to promote regular physical activities [28,29], mainly
aerobic activities [30], to decrease body adipose tissue
deposits, reduce blood pressure and increase insulin
sensivity [31,32]. The pharmacist can also offer nutri-
tional counselling for weight loss [33-35].On the other hand, the pharmacist should promote
secondary prevention in patients with diabetes, hyper-
tension or dyslipidemia [35,36]. In these patients, health
education at the community pharmacy has a very import-
ant role. As mentioned previously, some possible inter-
ventions that can be carried out on these patients include:
design of an exercise plan, recommendations for indivi-
dualised dietary measures, helping patients to give up
smoking, identification of possible errors in medication,
and advocacy of treatment adherence [35-38]. Diabetic
patients can be offered routine checks of distinct bio-
chemical parameters such as blood glucose or glycated
haemoglobin [36]. They can also be informed about the
acute or chronic complications of diabetes and guide-
lines for the correct handling and administration of
anti-diabetic medication such as insulin [36]. In patients
with arterial hypertension, it is very important to monitor
arterial pressure and restrict consumption of salt in food
[38,39]. The community pharmacy can also recommend
some dietary health measures to those patients who present
with dyslipidemia, such as a reduction in consumption of
fats or a physical exercise programme [40]. Many studies
demonstrate that all these interventions recommended
Figure 4 Error Bars (95% CI) of Cardiovascular Risk (Regicor) according to the diagnosis of premorbid metabolic syndrome and physical
inactivity. CI: Confidence Interval.
Figure 3 Error Bars (95% CI) of body mass index according to the diagnosis of premorbid metabolic syndrome and gender. CI: Confidence
Interval; BMI: body mass index.
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Figure 5 Error Bars (95% CI) of Cardiovascular Risk (Score) according to the diagnosis of premorbid metabolic syndrome and physical
inactivity. CI: Confidence Interval.
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significantly reduce the risk of suffering a cardiovascular
event [35,37-39].
The main aim for patients with pre-MetS is to maintain
a normal weight. The pharmacist should recommend that
patients with pre-MetS have a healthy, balanced diet. It is
vital that these patients increase their intake of fresh fruit
and vegetables and avoid food and drinks which are
rich in sugar and fats, particularly saturated fats [34,35]. In
our study, almost 90% of patients with pre-MetS were
overweight or obese and had higher values in all studied
variables than patients with a normal weight (BMI < 25).
We found an optimal cutoff point in BMI of 25 Kg/m2
that shows the studied variables in the normal range.
According to these results, BMI could be included as a
pre-MetS diagnostic criteria risk factor. However, BMI
is highly correlated with waist circumference, one of
five included risk factors and, in addition, evidence has
shown that waist circumference is a better body weight
variable for predicting cardiometabolic diseases [41,42].Limitations
The present study does not attempt to extrapolate the
results to the target population but rather to estimate
the prevalence of pre-MetS in patients who regularly
attend community pharmacies. Methodologically, this study
has some biases: The non-inclusion of patients over 65 with greater
prevalence of this syndrome.
 Recruitment of individuals from a pharmacy probably
includes a similar population to that included in
epidemiological studies from primary care. It is logical
to assume that more ill patients will go to buy
medicines than healthy people, although sometimes
the healthy relatives buy the drugs.
 Low patient recruitment considering the
involvement of 23 centres over a year which
represents an average rate of 1.6 patients per
pharmacy/per week.
Conclusions
The prevalence of pre-MetS in our study (21.9%) was
very similar to that found in other studies carried out in
Primary Care in Spain. The results of this study confirm
emergent cardiometabolic risk factors such as hypertension,
obesity and physical inactivity.
Our study highlights the strategic role of the pharmacist
and the community pharmacy in the detection of cardio-
metabolic risk factors in the apparently healthy population.
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